View More Recent Stories

Apr 25, 2025 01:01PM Nurix Therapeutics (NRIX) Presents Positive Preclinical Data
Apr 17, 2025 07:01AM Nurix Therapeutics (NRIX) Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions
Apr 10, 2025 10:23AM Nurix (NRIX) PT Lowered to $30 at UBS
Apr 9, 2025 08:00AM Nurix (NRIX) PT Lowered to $35 at Stifel
Apr 9, 2025 07:05AM Nurix (NRIX) PT Lowered to $30 at Stephens
Apr 9, 2025 05:28AM Stifel Reiterates Buy Rating on Nurix (NRIX)
Apr 9, 2025 05:15AM BTIG Reiterates Neutral Rating on Nurix (NRIX)
Apr 3, 2025 06:50AM H.C. Wainwright Reiterates Buy Rating on Nurix (NRIX)
Apr 2, 2025 07:03AM Nurix Therapeutics (NRIX) Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases
Mar 17, 2025 07:01AM Nurix Therapeutics (NRIX) Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia
Mar 14, 2025 04:03PM Nurix Therapeutics (NRIX) announces inducement grants
Mar 13, 2025 04:00PM Nurix Therapeutics (NRIX) Appoints Roy D. Baynes to its Board
Jan 29, 2025 10:10AM Nurix (NRIX) PT Raised to $36 at Stifel
Jan 29, 2025 07:59AM Nurix (NRIX) PT Lowered to $28 at Needham
Jan 29, 2025 06:39AM Nurix (NRIX) PT Raised to $36 at H.C. Wainwright
Jan 28, 2025 04:23PM Nurix Therapeutics, Inc. (NRIX) Misses Q4 EPS by 7c
Jan 22, 2025 07:00AM Nurix Therapeutics (NRIX) Appoints John Northcott as Chief Commercial Officer
Dec 22, 2024 04:00AM Barclays shares outlook for Biotech in 2025, names preferred stocks
Dec 21, 2024 10:00AM RBC report: Biotech faces both uncertainty and growth opportunities in 2025
Dec 19, 2024 07:01AM Nurix Therapeutics (NRIX) Receives FDA Fast Track Designation for NX-5948
Dec 11, 2024 07:12AM Nurix (NRIX) PT Raised to $35 at H.C. Wainwright
Dec 5, 2024 04:09PM BMO Capital Starts Nurix (NRIX) at Outperform
Nov 20, 2024 04:00PM Nurix Therapeutics (NRIX) Receives PRIME Designation from the European Medicines Agency for NX-5948
Oct 24, 2024 03:35AM UBS Starts Nurix (NRIX) at Buy
Oct 21, 2024 06:55AM Nurix (NRIX) PT Raised to $30 at H.C. Wainwright
Oct 16, 2024 04:36PM Nurix Therapeutics (NRIX) Appoints Anil Kapur to its Board
Oct 15, 2024 06:19AM Wells Fargo Reiterates Overweight Rating on Nurix (NRIX)
Oct 14, 2024 08:34AM Nurix (NRIX) PT Raised to $34 at Stifel
Oct 14, 2024 07:36AM Piper Sandler Reiterates Overweight Rating on Nurix (NRIX)
Oct 14, 2024 03:50AM Nurix Therapeutics, Inc. (NRIX) Reports In-Line Q3 EPS
Oct 11, 2024 05:25AM Jefferies Starts Nurix (NRIX) at Buy
Oct 1, 2024 01:44PM Truist Securities Reiterates Buy Rating on Nurix (NRIX)
Sep 5, 2024 04:09PM Baird Assumes Nurix (NRIX) at Outperform
Aug 14, 2024 07:42AM Nurix (NRIX) PT Raised to $27 at Oppenheimer
Jul 31, 2024 06:03AM Truist Securities Starts Nurix (NRIX) at Buy
Jul 12, 2024 02:13PM Nurix (NRIX) PT Raised to $30 at Stifel
Jul 12, 2024 08:19AM Piper Sandler Reiterates Overweight Rating on Nurix (NRIX)
Jul 12, 2024 07:13AM Nurix (NRIX) PT Lowered to $29 at Needham
Jul 12, 2024 06:22AM Nurix (NRIX) PT Raised to $27 at RBC Capital
Jul 11, 2024 04:34PM Nurix Therapeutics, Inc. (NRIX) Misses Q2 EPS by 8c
Jun 27, 2024 06:15AM Nurix (NRIX) PT Raised to $26 at RBC Capital
Jun 18, 2024 06:44AM Nurix (NRIX) PT Raised to $26 at H.C. Wainwright
Jun 17, 2024 07:56AM Piper Sandler Reiterates Overweight Rating on Nurix (NRIX)
Jun 11, 2024 06:11AM RBC Capital Reiterates Outperform Rating on Nurix (NRIX)
View More Recent Stories